Eli Lilly to supply 650,000 additional Covid doses to US Govt
New Delhi: Eli Lilly and Co said on Wednesday the U.S. government has purchased 650,000 additional doses of its Covid-19 antibody drug for $812.5 million.The doses will be delivered through Jan. 31, with at least 350,000 delivered in December, the company said.The drug has been authorized by the U.S. Food and Drug Administration for emergency use, and the government bought 300,000 doses...
Login or Register to read the full article
New Delhi: Eli Lilly and Co said on Wednesday the U.S. government has purchased 650,000 additional doses of its Covid-19 antibody drug for $812.5 million.
The doses will be delivered through Jan. 31, with at least 350,000 delivered in December, the company said.
The drug has been authorized by the U.S. Food and Drug Administration for emergency use, and the government bought 300,000 doses in October.
The new purchase is part of a U.S. government deal to secure nearly 1 million doses of Lilly's bamlanivimab, a treatment similar to Regeneron Pharmaceuticals Inc's Covid-19 antibody therapy that U.S. President Donald Trump received in October during his illness.
The treatments belong to a class of drugs called monoclonal antibodies that are manufactured copies of antibodies created by the body to fight against an infection.
Lilly anticipates manufacturing up to one million doses of bamlanivimab by the end of 2020 for use around the world through early next year.
Read also: Eli Lilly arthritis drug baricitinib in combination with remdesivir gets USFDA okay to treat Covid
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd